- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00343382
Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer
Pilocarpine for Vaginal Dryness: A Phase III Randomized, Double Blind, Placebo-Controlled Study
RATIONALE: Pilocarpine may decrease vaginal dryness and improve quality of life in patients with breast cancer It is not yet known whether pilocarpine is more effective than a placebo in treating vaginal dryness in patients with breast cancer.
PURPOSE: This randomized phase III trial is studying pilocarpine to see how well it works compared to a placebo in treating vaginal dryness in patients with breast cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to age (18 to 45 vs 46 to 55 vs 56 to 65 vs > 65), concurrent tamoxifen therapy (yes vs no vs unknown [e.g., on a blinded clinical study]), concurrent aromatase inhibitor therapy (yes vs no vs unknown [e.g., on a blinded clinical study]), and perception of severity of vaginal symptoms at baseline (mild vs moderate vs severe). Patients are randomized to 1 of 4 treatment arms. The primary and secondary objectives of the study are described below.
OBJECTIVES:
Primary
- Determine the effectiveness of pilocarpine hydrochloride for alleviation of vaginal dryness in patients with breast cancer.
Secondary
- Evaluate any toxicities arising from pilocarpine hydrochloride in these patients.
- Evaluate quality of life of these patients treated with pilocarpine hydrochloride.
Quality of life was assessed at baseline and then weekly for 6 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Aurora Presbyterian Hospital
-
Boulder, Colorado, United States, 80301-9019
- Boulder Community Hospital
-
Colorado Springs, Colorado, United States, 80933
- Penrose Cancer Center at Penrose Hospital
-
Denver, Colorado, United States, 80210
- Porter Adventist Hospital
-
Denver, Colorado, United States, 80220
- Rose Medical Center
-
Denver, Colorado, United States, 80218
- Presbyterian - St. Luke's Medical Center
-
Denver, Colorado, United States, 80204
- St. Anthony Central Hospital
-
Denver, Colorado, United States, 80218
- St. Joseph Hospital
-
Denver, Colorado, United States, 80224-2522
- CCOP - Colorado Cancer Research Program
-
Englewood, Colorado, United States, 80110
- Swedish Medical Center
-
Grand Junction, Colorado, United States, 81502
- St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
-
Greeley, Colorado, United States, 80631
- North Colorado Medical Center
-
Lone Tree, Colorado, United States, 80124
- Sky Ridge Medical Center
-
Longmont, Colorado, United States, 80501
- Hope Cancer Care Center at Longmont United Hospital
-
Loveland, Colorado, United States, 80539
- McKee Medical Center
-
Pueblo, Colorado, United States, 81004
- St. Mary - Corwin Regional Medical Center
-
Thornton, Colorado, United States, 80229
- North Suburban Medical Center
-
Wheat Ridge, Colorado, United States, 80033
- Exempla Lutheran Medical Center
-
-
Illinois
-
Bloomington, Illinois, United States, 61701
- St. Joseph Medical Center
-
Canton, Illinois, United States, 61520
- Graham Hospital
-
Carthage, Illinois, United States, 62321
- Memorial Hospital
-
Eureka, Illinois, United States, 61530
- Eureka Community Hospital
-
Galesburg, Illinois, United States, 61401
- Galesburg Cottage Hospital
-
Galesburg, Illinois, United States, 61401
- Galesburg Clinic, PC
-
Havana, Illinois, United States, 62644
- Mason District Hospital
-
Joliet, Illinois, United States, 60435
- Joliet Oncology-Hematology Associates, Limited - West
-
Macomb, Illinois, United States, 61455
- Mcdonough District Hospital
-
Moline, Illinois, United States, 61265
-
Moline, Illinois, United States, 61265
- Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
-
Monmouth, Illinois, United States, 61462
- OSF Holy Family Medical Center
-
Normal, Illinois, United States, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, United States, 61761
- Community Cancer Center
-
Ottawa, Illinois, United States, 61350
- Community Hospital of Ottawa
-
Ottawa, Illinois, United States, 61350
- Oncology Hematology Associates of Central Illinois, PC - Ottawa
-
Pekin, Illinois, United States, 61554
- Cancer Treatment Center at Pekin Hospital
-
Peoria, Illinois, United States, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, United States, 61614
- Proctor Hospital
-
Peoria, Illinois, United States, 61637
- OSF St. Francis Medical Center
-
Peoria, Illinois, United States, 61615
- CCOP - Illinois Oncology Research Association
-
Peoria, Illinois, United States, 61615
- Oncology Hematology Associates of Central Illinois, PC - Peoria
-
Peru, Illinois, United States, 61354
- Illinois Valley Community Hospital
-
Princeton, Illinois, United States, 61356
- Perry Memorial Hospital
-
Spring Valley, Illinois, United States, 61362
- St. Margaret's Hospital
-
-
Indiana
-
Elkhart, Indiana, United States, 46515
- Elkhart General Hospital
-
Kokomo, Indiana, United States, 46904
- Howard Community Hospital
-
La Porte, Indiana, United States, 46350
- Center for Cancer Therapy at LaPorte Hospital and Health Services
-
South Bend, Indiana, United States, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, United States, 46601
- CCOP - Northern Indiana CR Consortium
-
South Bend, Indiana, United States, 46617
- Saint Joseph Regional Medical Center
-
South Bend, Indiana, United States, 46617
- South Bend Clinic
-
-
Iowa
-
Ames, Iowa, United States, 50010
- McFarland Clinic, PC
-
Bettendorf, Iowa, United States, 52722
-
Cedar Rapids, Iowa, United States, 52403
- Cedar Rapids Oncology Associates
-
Cedar Rapids, Iowa, United States, 52403
- Mercy Regional Cancer Center at Mercy Medical Center
-
Ottumwa, Iowa, United States, 52501
- McCreery Cancer Center at Ottumwa Regional
-
Sioux City, Iowa, United States, 51101
- Siouxland Hematology-Oncology Associates, LLP
-
Sioux City, Iowa, United States, 51104
- St. Luke's Regional Medical Center
-
Sioux City, Iowa, United States, 51104
- Mercy Medical Center - Sioux City
-
-
Kansas
-
Chanute, Kansas, United States, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, United States, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, United States, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Independence, Kansas, United States, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, United States, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, United States, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, United States, 67901
- Southwest Medical Center
-
Newton, Kansas, United States, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, United States, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, United States, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, United States, 67042
- Cancer Center of Kansas, PA - Salina
-
Wellington, Kansas, United States, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, United States, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, United States, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, United States, 67214
- CCOP - Wichita
-
Wichita, Kansas, United States, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, United States, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, United States, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, United States, 48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, United States, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, United States, 49307
- Mecosta County Medical Center
-
Dearborn, Michigan, United States, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Flint, Michigan, United States, 48503
- Hurley Medical Center
-
Flint, Michigan, United States, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, United States, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, United States, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, United States, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods, Michigan, United States, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Jackson, Michigan, United States, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, United States, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, United States, 48154
- St. Mary Mercy Hospital
-
Muskegon, Michigan, United States, 49443
- Mercy General Health Partners
-
Pontiac, Michigan, United States, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, United States, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, United States, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
St. Joseph, Michigan, United States, 49085
- Lakeland Regional Cancer Care Center - St. Joseph
-
Traverse City, Michigan, United States, 49684
- Munson Medical Center
-
Warren, Michigan, United States, 48093
- St. John Macomb Hospital
-
Wyoming, Michigan, United States, 49519
- Metro Health Hospital
-
-
Minnesota
-
Alexandria, Minnesota, United States, 56308
-
Bemidji, Minnesota, United States, 56601
- MeritCare Bemidji
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, United States, 55433
- Mercy and Unity Cancer Center at Mercy Hospital
-
Duluth, Minnesota, United States, 55805
- CCOP - Duluth
-
Duluth, Minnesota, United States, 55805-1983
- Duluth Clinic Cancer Center - Duluth
-
Duluth, Minnesota, United States, 55805
- Miller - Dwan Medical Center
-
Edina, Minnesota, United States, 55435
- Fairview Southdale Hospital
-
Fergus Falls, Minnesota, United States, 56537
-
Fridley, Minnesota, United States, 55432
- Mercy and Unity Cancer Center at Unity Hospital
-
Hutchinson, Minnesota, United States, 55350
- Hutchinson Area Health Care
-
Lichfield, Minnesota, United States, 55355
- Meeker County Memorial Hospital
-
Mankato, Minnesota, United States, 56002
- Immanuel St. Joseph's
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology Hematology, PA - Maplewood
-
Maplewood, Minnesota, United States, 55109
- HealthEast Cancer Care at St. John's Hospital
-
Minneapolis, Minnesota, United States, 55407
- Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
-
Minneapolis, Minnesota, United States, 55415
- Hennepin County Medical Center - Minneapolis
-
Robbinsdale, Minnesota, United States, 55422-2900
- Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic Cancer Center
-
Saint Cloud, Minnesota, United States, 56303
- CentraCare Clinic - River Campus
-
Saint Cloud, Minnesota, United States, 56303
- Coborn Cancer Center
-
Saint Louis Park, Minnesota, United States, 55416
- CCOP - Metro-Minnesota
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Cancer Center
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Shakopee, Minnesota, United States, 55379
- St. Francis Cancer Center at St. Francis Medical Center
-
St. Paul, Minnesota, United States, 55101
- Regions Hospital Cancer Care Center
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology Hematology, PA - Woodbury
-
-
Missouri
-
Springfield, Missouri, United States, 65802
- CCOP - Cancer Research for the Ozarks
-
Springfield, Missouri, United States, 65804
- St. John's Regional Health Center
-
Springfield, Missouri, United States, 65807
- Hulston Cancer Center at Cox Medical Center South
-
-
Montana
-
Billings, Montana, United States, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, United States, 59101
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Billings, Montana, United States, 59101
- Northern Rockies Radiation Oncology Center
-
Billings, Montana, United States, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, United States, 59107-7000
- Billings Clinic - Downtown
-
Butte, Montana, United States, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, United States, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, United States, 59405
-
Great Falls, Montana, United States, 59405-5309
- Big Sky Oncology
-
Great Falls, Montana, United States, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Havre, Montana, United States, 59501
- Northern Montana Hospital
-
Helena, Montana, United States, 59601
- St. Peter's Hospital
-
Kalispell, Montana, United States, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, United States, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, United States, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, United States, 59801
- Community Medical Center
-
Missoula, Montana, United States, 59804
- Guardian Oncology and Center for Wellness
-
Missoula, Montana, United States, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, United States, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68510
- Cancer Resource Center - Lincoln
-
Omaha, Nebraska, United States, 68106
- CCOP - Missouri Valley Cancer Consortium
-
Omaha, Nebraska, United States, 68122
- Immanuel Medical Center
-
Omaha, Nebraska, United States, 68124
- Alegant Health Cancer Center at Bergan Mercy Medical Center
-
Omaha, Nebraska, United States, 68131-2197
- Creighton University Medical Center
-
-
North Carolina
-
Rutherfordton, North Carolina, United States, 28139
- Rutherford Hospital
-
-
North Dakota
-
Fargo, North Dakota, United States, 58122
- CCOP - MeritCare Hospital
-
Fargo, North Dakota, United States, 58122
- MeritCare Broadway
-
-
Ohio
-
Bellefontaine, Ohio, United States, 43311
- Mary Rutan Hospital
-
Chillicothe, Ohio, United States, 45601
- Adena Regional Medical Center
-
Columbus, Ohio, United States, 43214-3998
- Riverside Methodist Hospital Cancer Care
-
Columbus, Ohio, United States, 43222
- Mount Carmel Health - West Hospital
-
Columbus, Ohio, United States, 43215
- CCOP - Columbus
-
Columbus, Ohio, United States, 43215
- Grant Medical Center Cancer Care
-
Columbus, Ohio, United States, 43228
- Doctors Hospital at Ohio Health
-
Delaware, Ohio, United States, 43015
- Grady Memorial Hospital
-
Lancaster, Ohio, United States, 43130
- Fairfield Medical Center
-
Marietta, Ohio, United States, 45750
- Strecker Cancer Center at Marietta Memorial Hospital
-
Newark, Ohio, United States, 43055
- Licking Memorial Cancer Care Program at Licking Memorial Hospital
-
Springfield, Ohio, United States, 45505
- Community Hospital of Springfield and Clark County
-
Springfield, Ohio, United States, 45504
- Mercy Medical Center
-
Westerville, Ohio, United States, 43081
- Mount Carmel St. Ann's Cancer Center
-
Zanesville, Ohio, United States, 43701
- Genesis - Good Samaritan Hospital
-
-
Oregon
-
Milwaukie, Oregon, United States, 97222
- Providence Milwaukie Hospital
-
Portland, Oregon, United States, 97216
- Adventist Medical Center
-
Portland, Oregon, United States, 97213-2967
- Providence Cancer Center at Providence Portland Medical Center
-
Portland, Oregon, United States, 97225
- CCOP - Columbia River Oncology Program
-
Portland, Oregon, United States, 97225
- Providence St. Vincent Medical Center
-
Tualatin, Oregon, United States, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18105
- Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- AnMed Cancer Center
-
Spartanburg, South Carolina, United States, 29303
- CCOP - Upstate Carolina
-
Spartanburg, South Carolina, United States, 29303
- Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, United States, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, United States, 57105
- Medical X-Ray Center, PC
-
Sioux Falls, South Dakota, United States, 57117-5039
- Sanford Cancer Center at Sanford USD Medical Center
-
-
Virginia
-
Richmond, Virginia, United States, 23298-0037
- Virginia Commonwealth University Massey Cancer Center
-
-
Washington
-
Vancouver, Washington, United States, 98668
- Southwest Washington Medical Center Cancer Center
-
-
Wisconsin
-
Fond du Lac, Wisconsin, United States, 54935
- Central Wisconsin Cancer Program at Agnesian HealthCare
-
Green Bay, Wisconsin, United States, 54307-3508
- St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54301-3526
- Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
-
Green Bay, Wisconsin, United States, 54303
- Green Bay Oncology, Limited at St. Mary's Hospital
-
Green Bay, Wisconsin, United States, 54303
- St. Mary's Hospital Medical Center - Green Bay
-
Marinette, Wisconsin, United States, 54143
- Bay Area Cancer Care Center at Bay Area Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Required Characteristics:
- Adult post menopausal women or women with no childbearing potential (≥ 18 years) with a history of breast cancer (currently no evidence of disease) or women who do not want to take vaginal estrogen for a fear of an increased risk of breast cancer. Postmenopausal status will be determined by the primary physician.
- Significant vaginal complaints defined as persistent vaginal dryness and/or itching of sufficient severity to make a patient desire therapeutic intervention. Symptoms should have been present ≥ 2 months prior to randomization.
- Life expectancy > 6 months
- Ability to complete questionnaire(s) by themselves or with assistance.
Contraindications:
- Initiation or discontinuation of tamoxifen or aromatase inhibitors ≤2 months prior to randomization or plans to initiate or discontinue any of these medications during the 6-week study.
- Active vaginal infection
- Concurrent chemotherapy
- Acute iritis
- Current or past use of pilocarpine (regardless of purpose)
- Planned use of any vaginal preparations during the study period (including any over the counter or herbal preparations). Note: Lubricants used during sexual intercourse are permitted.
- Use of any vaginal preparations ≤ 1 week prior to study entry (Exception: If patient has used vaginal preparations during the previous week but will stop, then they can be placed on study with plans to start with pretreatment questionnaire one week later). Note: Lubricants used during sexual intercourse are permitted.
- Current (≤ 4weeks prior to randomization), or planned during the study period, use of any estrogen product.
- A diagnosis of asthma, COPD, CAD or narrow angle glaucoma, or known cholelithiasis.
- Hepatic or renal insufficiency defined as a history of an elevation of SGOT ≥1.5 x ULN or creatinine ≥ 1.5 x ULN within the past year.
- Concurrent use of other anticholinergics
- Use of pharmacologic soy preparations
- Known history of cardiac arrhythmia. (Patients with occasional PVC's or PAC's that do not require treatment are eligible.)
- Prior or concurrent pelvic radiation therapy
- Prior radical pelvic surgery (TAH/BSO is allowed)
- Use of beta adrenergic antagonists
Diagnosis of any of the following conditions:
- Vulvar and vaginal dysplasia
- Essential vulvodynia
- Vulvar vestibulitis
- Vaginal prolapse
- Bartholin cyst/abscess
- History of Bartholin gland surgery
- Lichen sclerosis
- Lichen planus of the vulvovaginal region
- Desquamative vaginitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I
Patients receive oral pilocarpine hydrochloride once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
|
Given orally
|
Experimental: Arm II
Patients receive oral pilocarpine hydrochloride once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
|
Given orally
|
Placebo Comparator: Arm III
Patients receive oral placebo once a day for 3 days, twice a day for 3 days, three times a day for 3 days, and then 4 times a day for up to 6 weeks in the absence of unacceptable toxicity.
|
Given orally
|
Placebo Comparator: Arm IV
Patients receive oral placebo once a day for 3 days and then twice a day for up to 6 weeks in the absence of unacceptable toxicity.
|
Given orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average Vaginal Dryness Scores Via Area Under the Curve (AUC) Summary Statistics
Time Frame: Baseline to Week 6
|
Vaginal dryness was measured by the numerical analogue scale at baseline and through the six weeks of treatment.
The item scores was transformed into 0 to 100 scales with 0=poor quality of life (QOL) and 100=best possible QOL.
The average AUC values were calculated by dividing 6 from AUC values for participants who completed item on all 6 weeks.
If a participant completed the item at baseline, week 1, 2 and 3 but did not complete the item at week 4 to week 6, the AUC values of the item was prorated, which is (((AUC values * 6) / 3) / 6).
The average pro-rated AUC for vaginal dryness scores was compared in each of the Pilocarpine arms against the collective placebo arm.
|
Baseline to Week 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) 3.0
Time Frame: End of 6 weeks
|
CTCAE Grading: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening, Grade 5=Death.
|
End of 6 weeks
|
Average AUC Summary Statistics for the Impact of Vaginal Dryness for Activities of Daily Living
Time Frame: Baseline to Week 6
|
The impact of vaginal dryness for activities of daily living (ADL) were measured by the numerical analogue scales at baseline and through the six weeks of treatment.
The item scores was transformed into 0 to 100 scales with 0=poor quality of life (QOL) and 100=best possible QOL.
The average AUC values were calculated by dividing 6 from AUC values for participants who completed item on all 6 weeks.
If a participant completed the item at baseline, week 1, 2 and 3 but did not complete the item at week 4 to week 6, the AUC values of the item was prorated, which is (((AUC values * 6) / 3) / 6).
The average pro-rated AUC scores was compared in each of the Pilocarpine arms against the collective placebo arm.
|
Baseline to Week 6
|
Change From Baseline to Week 6 on the Impact of Vaginal Dryness for Activities of Daily Living Scores
Time Frame: Baseline and Week 6
|
The impact of vaginal dryness for activities of daily living (ADL) were measured by the numerical analogue scales at baseline and through the six weeks of treatment.
The item scores was transformed into 0 to 100 scales with 0=poor quality of life (QOL) and 100=best possible QOL.
The change from baseline scores was calculated by subtracting the baseline item scores from the scores at 6 week.
|
Baseline and Week 6
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Cholinergic Agonists
- Miotics
- Muscarinic Agonists
- Pilocarpine
Other Study ID Numbers
- NCCTG-N04CA
- NCI-2009-00648 (Registry Identifier: CTRP (Clinical Trials Reporting System))
- CDR0000482969 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States